ProBiotix Health eyes Eastern European market with new partnership
The partnership will first focus on the Ukrainian market, which the company hopes will provide a springboard into Uzbekistan and other countries in the region.
Deutsch-Pharm will initially distribute YourBiotixX3, which targets cholesterol, and YourBiotixVH, which targets general vascular health. Both products will be introduced under the Deutsch-Pharm brand and sold through brick-and-mortar pharmacies as well as online stores.
“The partnership with Deutsch-Pharm is a significant milestone for ProBiotix Health, marking our entry into the Ukrainian market with strong, reputable local partners,” said Steen Andersen, ProBiotix CEO. “It will impact our aim to improve access to precision probiotics targeting cardiometabolic health, particularly cholesterol management, in a country with high cardiovascular disease rates.”
Deutsch-Pharm is one of the leading pharmaceutical product distributors in Ukraine, working with over 9,000 customers and partners in the country.
Strong opportunity for growth
Ukraine has a population of 38 million plus a significant elderly population. The World Health Organization estimates that over 40% of the adult population has elevated cholesterol levels.
Andersen predicts a growing demand in the country for healthy aging products driven by interest in evidence-based preventative health solutions. Until recently, no natural preventative, clinically documented dietary supplements have been available to consumers in Ukraine.
“Ukraine, and Eastern Europe, have a lack of access to scientifically validated natural supplements for cardiometabolic health,” he said. “Until now, there have been limited options for consumers seeking preventive, non-pharmaceutical solutions for cholesterol management.”
This starts with educating consumers about the potential benefits of probiotics for key areas like blood pressure and cholesterol.
“Awareness around probiotics for cardiometabolic health is another growth opportunity,” Anderson said.
“While probiotics are well-known for gut health, their role in supporting cardiovascular biomarkers such as cholesterol and blood pressure is less well-known—offering a strong opportunity for education and market growth. This could potentially set a path for similar future partnerships across Eastern Europe.”
Focused on innovation
As well as expanding its global reach, Andersen said that ProBiotix is focused squarely on innovation. This includes investing in more clinical research to address a broader range of cardiometabolic health issues.
“A key future direction will be identifying new probiotic strains to support a wider variety of health areas associated with healthy aging,” he said.
“Alongside this, we will initiate new clinical research to validate these strains and their health benefits, ensuring our products are at the forefront of scientific development. We will also focus on developing more finished formulations, enabling our IP-protected precision probiotics to be commercialized for easy access and consumption by end-users.”
